Study of VV-14305 for thyroid eye disease
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests an investigational medication for thyroid eye disease, which causes bulging eyes and discomfort. The treatment is given as an injection near the eye, and the study will last about 12 months to see how safe and effective it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a diagnosis of chronic, moderate-to-severe thyroid eye disease.
- Your thyroid function must be stable or you must be receiving treatment for mild thyroid imbalance.
- You must not have other serious eye conditions that could interfere with the study.
- You must not have diabetes.
- You must be willing to stop certain medications (like blood thinners or NSAIDs) for 10 days before the study injection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MHB018A for chronic thyroid eye disease (TED)—a condition where the eyes become inflamed and swollen due to thyroid problems. The study aims to see if this treatment can reduce eye inflammation and improve symptoms in people who have had TED for over a year.
This study tests whether a new medicine called MHB018A can reduce swelling and inflammation in thyroid eye disease (TED)—a condition where the immune system attacks tissues around the eyes, causing them to swell, bulge, and become uncomfortable. Researchers will compare MHB018A to placebo (a fake medicine) to see if it helps improve symptoms and appearance.
This trial tests a new drug called ZL-1109 for people with active, moderate to severe thyroid eye disease (TED). It aims to see if the drug can reduce symptoms like bulging eyes and help patients feel better without using steroids.
This study tests a new medication called MHB018A for people with chronic Thyroid Eye Disease (TED) that is moderate to severe. It aims to see if the drug can help improve symptoms and quality of life over time.
This study offers continued treatment with MHB018A for patients with thyroid eye disease (swelling and bulging of the eyes from thyroid problems) who either didn't improve enough after 24 weeks of treatment or whose symptoms came back. The goal is to see if more treatment can help reduce eye bulging and other symptoms.
This study tests a new medication called GenSci098 for people with active thyroid eye disease. It aims to reduce eye symptoms like redness, swelling, and bulging, and improve quality of life.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.